Paragonix touts performance of donor-heart transport technology

  (Image courtesy of Paragonix Technologies) Paragonix Technologies (Braintree, Mass.) said today that its SherpaPak donor-heart transport system has been used successfully at Massachusetts General Hospital in Boston and other transplant centers around the U.S. and Europe. The SheraPak combines cooling technology with safe, consistent methods for cold ischemic storage and transport of donor organs, according to the company, which is also developing and commercializing SherpaLung to transport donated lungs to recipients. Real-time reporting of preservation temperature allows for continuous monitoring of transport conditions of the donor heart. When the transport is completed, these data are downloaded to Bluetooth-enabled devices for record-keeping and sharing among the transplant team. Get the full story on our sister site, Medical Design &Outsourcing. The post Paragonix touts performance of donor-heart transport technology appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Cardiac Implants Cardiovascular Transplants internationalsocietyofheartandlungtransplantation Massachusetts General Hospital Paragonix Technologies Source Type: news

Related Links:

Discussion: Both fetoscopic and US-guided IUHCT were technically feasible, but fetoscopy caused more intraoperative complications in our pilot series. The discrepancy in chimerism detection predicts the challenges in long-term surveillance of donor-cell chimerism. Further studies of long-term outcomes in the non-human primate are valuable for the development of clinical protocols for IUHCT.Fetal Diagn Ther
Source: Fetal Diagnosis and Therapy - Category: Perinatology & Neonatology Source Type: research
A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells — which can give rise to every cell type in the body and which can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.The technique uses structures called artificial thymic organoids, which work by mimicking the environment of the thymus, the organ in which T cells develop from blood stem cells.T cells are cells of the immune system that fight infections, but also have the potential to eliminate cancer cells. The ability to create them from self-renewing pluripotent ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Despite advances in device technology and treatment strategies infection remains a major cause of adverse events (AE) in mechanical circulatory support (MCS) patients. To characterize the epidemiology of MCS infection we examined the type, location, and timing of infection in the International Society for Heart and Lung Transplantation Registry (ISHLT) for Mechanically Assisted Circulatory Support (IMACS) over 3 years, 2013-2015.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
We read with great interest the review by Yanagawa et al, entitled Surgery for tumors of the heart,1 where the authors thoroughly review cardiac tumors classification, diagnosis sequence as well as the suggested method of treatment for the different kinds of tumors. The authors address sarcoma's as one of the rare malignant tumors and suggest a two-step surgical approach to sarcoma that involve the heart and lung.
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ADULT – Letter to the Editor Source Type: research
Chronic lung allograft dysfunction or CLAD, encompasses a variety of phenotypes including both obstructive and restrictive phenotypes as detected by pulmonary function testing (PFTs), and has advanced the understanding of current clinical guidelines1-5. From the initial classification of chronic lung allograft rejection based primarily on pulmonary function testing, clinical guidelines now encompass CLAD phenotypes, presumed causes, characteristic imaging findings, and refinement of histopathological grades.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
By ANISH KOKA MD  The message comes in over the office slack line at 1:05 pm. There are four patients in rooms, one new, 3 patients in the waiting room. Really, not an ideal time to deal with this particular message. “Kathy the home care nurse for Mrs. C called and said her weight yesterday was 185, today it is 194, she has +4 pitting edema, heart rate 120, BP 140/70 standing, 120/64 sitting” I know Mrs. C well. She has severe COPD from smoking for 45 of the last 55 years. Every breath looks like an effort because it is. The worst part of it all is that Mrs. C just returned home from the hospital just days...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Hospitals Medicare Anish Koka hospital readmissions HRRP MedPAC Source Type: blogs
Left Ventricular Assist Device (LVAD) support is a well established therapy for treatment of adult patients with end-stage heart failure (ESHF),1 in whom several types of devices varying in location, pump size, mechanics, and design are ‘officially’ available in the market. On the contrary, children with ESHF refractory to conventional therapy have much fewer ‘official’ and well-accepted options which require a continuous hospitalization and hinder patients’ mobility.2-13
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research
68 year old man from Bangalore, got a new life as he underwent heart and lungs transplant at Narayana Health City, Bangalore. The donor is a 24yr old male fr...
Source: The Economic Times - Category: Consumer Health News Source Type: news
It is with great interest that we read the case report by Mannem and colleagues.1 Unfortunately, their patient died within 30 days of lung transplantation from acute lung injury due to a pro-inflammatory state caused by flooded recipient-derived abnormal macrophage in the lungs. The authors concluded that transplanting patients with an orphan lung condition like Niemann ‒Pick disease carries a higher risk of complications, as the effect of the underlying disease on the post-operative course is difficult to predict.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: CASE ANECDOTES, COMMENTS AND OPINIONS Source Type: research
More News: Blogging | Cardiology | Cardiovascular | Heart | Heart Transplant | Hospitals | Lung Transplant | Transplant Surgery | Transplants